Merck reports Phase 3 win for sac-TMT in endometrial cancer: full analysis

Merck has reported a pivotal Phase 3 win for sacituzumab tirumotecan in advanced or recurrent endometrial cancer, saying the TroFuse-005 study met its primary endpoints of overall survival and progression-free survival at a prespecified interim analysis. According to the company, the investigational TROP2-directed antibody-drug conjugate outperformed physician’s choice chemotherapy, defined in the trial as doxorubicin or paclitaxel, in patients previously treated with platinum-based chemotherapy and anti-PD-1/PD-L1 immunotherapy. Objective response rate, a key secondary endpoint, was also met. (merck.com)

The result matters because this is a difficult treatment setting with limited options after prior platinum and immunotherapy exposure. TroFuse-005, also listed as NCT06132958 and associated with GOG-3095/ENGOT-en23, was designed as a global, randomized, open-label Phase 3 trial comparing sac-TMT monotherapy with investigator’s choice chemotherapy in this post-platinum, post-immunotherapy population. Merck is framing the readout as the first global Phase 3 study to show statistically significant improvements in both overall survival and progression-free survival for an antibody-drug conjugate in this endometrial cancer setting. (merck.com)

Sac-TMT, also known as MK-2870, targets TROP2 and delivers a belotecan-derived payload. Merck’s pipeline materials show the asset is part of a broader collaboration with Sichuan Kelun-Biotech and is being developed across a wide range of tumor types, including endometrial, cervical, bladder, ovarian, gastric, and non-small cell lung cancers. That broader development footprint helps explain why investors and oncology watchers are paying close attention to each late-stage readout: a positive Phase 3 result in one tumor type can strengthen confidence in the platform and accelerate interest in adjacent indications. (merck.com)

So far, Merck has shared only top-line results, not hazard ratios, median survival figures, subgroup analyses, or a detailed safety update. That leaves important questions unanswered, including the magnitude of benefit, tolerability relative to standard chemotherapy, and whether benefit was consistent across histologies such as carcinosarcoma, which trial materials indicate were included in the study population. Full presentation of the dataset will be important for clinicians, payers, and guideline groups assessing where sac-TMT could fit if it reaches regulators. (merck.com)

There wasn’t much independent expert reaction available yet in the immediate aftermath of the announcement, which is common for a top-line press release ahead of a conference presentation. Still, the broader endometrial cancer field has been actively looking for better options after platinum and immunotherapy, and ongoing Merck-sponsored work suggests the company is already trying to move sac-TMT earlier in care. One example is TroFuse-033, a first-line maintenance study in mismatch repair-proficient endometrial cancer testing sac-TMT plus pembrolizumab against pembrolizumab alone. (cancer.gov)

Why it matters: For veterinary professionals, this is mostly a horizon-scanning story, not a practice-changing one. But it does offer a useful signal about where oncology drug development is headed. Antibody-drug conjugates are becoming a central modality in human cancer treatment, and successful TROP2-directed programs may influence comparative oncology research, biomarker conversations, and future interest in adapting targeted payload-delivery strategies for animal patients. Veterinary oncologists, industry teams, and translational researchers often watch these late-stage human readouts because they can shape partnership activity, technology licensing, and the next wave of platform science that eventually crosses into animal health. (merck.com)

What to watch: The next step is full data disclosure, likely at a major oncology meeting or in a peer-reviewed paper, followed by any regulatory discussions or filing plans. Key issues to watch will be the size of the survival benefit, the safety profile, and whether Merck can translate this result into a broader endometrial cancer strategy that includes earlier-line use and combination regimens. (merck.com)